Orally inhaled dihydroergotamine (DHE) is a newly developed formulation of DHE for the treatment of acute migraine attack and is undergoing FDA review.
Abstract
Orally inhaled dihydroergotamine (DHE) is a newly developed formulation of DHE for the treatment of acute migraine attack and is undergoing FDA review. This new agent provides an alternative to nonsteroidal anti-inflammatory drugs and triptans. In clinical trials, orally inhaled DHE was effective compared with placebo in relieving headache, nausea, phonophobia, and photophobia. No serious adverse events were documented; mild adverse effects included poor taste, nausea, coughing, and vomiting. Orally inhaled DHE has not yet been approved for use, so final dosing and cost information is not available. No head-to-head trials have been conducted to compare orally inhaled DHE with other medications to treat acute migraine attacks, so further studies may be necessary to determine comparative efficacy. Orally inhaled DHE may provide an effective option for patients with moderate to severe acute migraine attack. (Formulary. 2012;47:54-57)
Migraine is a chronic and debilitating neurologic disorder characterized by severe headaches, nausea, vomiting, photophobia, and phonophobia.1 Migraines vary greatly in frequency, duration, and level of disability in affected patients.1
Dihydroergotamine (DHE) has been used intravenously, subcutaneously, and intranasally for the treatment of migraines.1 These formulations are effective and are reasonable choices in patients with moderate to severe migraine and in those whose mild to moderate headaches have failed to respond to other migraine treatments. A major limitation to the currently available DHE formulations is that the delivery route may be inconvenient for the patient. Orally inhaled DHE (Levedex, MAP Pharmaceuticals Inc) is under investigation for treatment of migraine.
CHEMISTRY AND PHARMACOLOGY
DHE interacts with adrenergic, dopaminergic, and serotonergic 5-hydroxytryptamine (5-HT) receptors. The affected 5-HT subtypes include 5-HT1A, 1B, 1D, 1F, 2A, 2C, 3, and 4.2 5-HT1B agonism leads to intracranial extracerebral blood vessel constriction within the meninges, which is thought to be responsible for producing pain.2 The primary effect of DHE occurs in the brainstem, where its serotonergic effects work to reverse vasodilation, reduce pain signal transmission, and halt other ascending pathways to the cortex that are related to photophobia and phonophobia.2
PHARMACOKINETICS
Orally inhaled DHE is rapidly and completely absorbed in the plasma. In healthy volunteers administered a 0.88-mg systemic equivalent dose, tmax was 12 minutes, half-life was 11 hours, and Cmax was 3648 pg/mL.3 When orally inhaled DHE was evaluated in patients with asthma, tmax was 9.6 minutes, half-life was 9.5 hours, and Cmax was 4097 pg/mL with a 1-mg systemic equivalent dose.4
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.